Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, Li H, De Costa A, Li Y, Chen Y, Easton A, Yee-Toy NC, Chen FZ, Gorlatov S, Barat B, Huang L, Wolff CR, Hooley J, Hotaling TE, Gaynutdinov T, Ciccarone V, Tamura J, Koenig S, Moore PA, Bonvini E, Loo D. Scribner JA, et al. Among authors: ciccarone v. Mol Cancer Ther. 2020 Nov;19(11):2235-2244. doi: 10.1158/1535-7163.MCT-20-0116. Epub 2020 Sep 23. Mol Cancer Ther. 2020. PMID: 32967924
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton AN, Li JC, Rillema JR, Licea M, Fieger C, Liang TW, Mather JP, Koenig S, Stewart SJ, Johnson S, Bonvini E, Moore PA. Loo D, et al. Among authors: ciccarone v. Clin Cancer Res. 2012 Jul 15;18(14):3834-45. doi: 10.1158/1078-0432.CCR-12-0715. Epub 2012 May 21. Clin Cancer Res. 2012. PMID: 22615450
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer.
Moore PA, Shah K, Yang Y, Alderson R, Roberts P, Long V, Liu D, Li JC, Burke S, Ciccarone V, Li H, Fieger CB, Hooley J, Easton A, Licea M, Gorlatov S, King KL, Young P, Adami A, Loo D, Chichili GR, Liu L, Smith DH, Brown JG, Chen FZ, Koenig S, Mather J, Bonvini E, Johnson S. Moore PA, et al. Among authors: ciccarone v. Mol Cancer Ther. 2018 Aug;17(8):1761-1772. doi: 10.1158/1535-7163.MCT-17-1086. Epub 2018 Jun 4. Mol Cancer Ther. 2018. PMID: 29866746
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Scribner JA, Hicks SW, Sinkevicius KW, Yoder NC, Diedrich G, Brown JG, Lucas J, Fuller ME, Son T, Dastur A, Hooley J, Espelin C, Themeles M, Chen FZ, Li Y, Chiechi M, Lee J, Barat B, Widjaja L, Gorlatov S, Tamura J, Ciccarone V, Ab O, McEachem KA, Koenig S, Westin EH, Moore PA, Chittenden T, Gregory RJ, Bonvini E, Loo D. Scribner JA, et al. Among authors: ciccarone v. Mol Cancer Ther. 2022 Jul 5;21(7):1047-1059. doi: 10.1158/1535-7163.MCT-21-0915. Mol Cancer Ther. 2022. PMID: 35511740
Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.
Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, Yang Y, Jin L, Ciccarone V, Moore PA, Koenig S, Bonvini E. Johnson S, et al. Among authors: ciccarone v. J Mol Biol. 2010 Jun 11;399(3):436-49. doi: 10.1016/j.jmb.2010.04.001. Epub 2010 Apr 9. J Mol Biol. 2010. PMID: 20382161
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, Shah K, Jin L, Zhang S, He L, Zhang T, Ciccarone V, Koenig S, Bonvini E, Johnson S. Moore PA, et al. Among authors: ciccarone v. Blood. 2011 Apr 28;117(17):4542-51. doi: 10.1182/blood-2010-09-306449. Epub 2011 Feb 7. Blood. 2011. PMID: 21300981 Free article.
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E. Nordstrom JL, et al. Among authors: ciccarone v. Breast Cancer Res. 2011;13(6):R123. doi: 10.1186/bcr3069. Epub 2011 Nov 30. Breast Cancer Res. 2011. PMID: 22129105 Free PMC article.
Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, Rainey GJ, Ciccarone V, Zhang T, Shah K, Jin L, Ning L, Minor T, Moore PA, Koenig S, Johnson S, Bonvini E. Veri MC, et al. Among authors: ciccarone v. Arthritis Rheum. 2010 Jul;62(7):1933-43. doi: 10.1002/art.27477. Arthritis Rheum. 2010. PMID: 20506263 Free article.
37 results